Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04746976 · ClinicalTrials.gov registry record
Study of Diroximel Fumarate in the Real-World Setting
A clinical trial, sponsored by Biogen.
- Terminated
- Registry status
- 75
- Enrollment target
NCT04746976: Clinical Trial study, sponsored by Biogen.
NCT04746976 is a clinical trial that was terminated before completion, run by Biogen. The registered enrollment target is 75 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04746976 was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- 75 participants
- Enrollment target
Study Summary
The primary objective of the study is to characterize the persistence to therapy in participants with relapsing forms of multiple sclerosis (RMS) treated with diroximel fumarate (DRF) in routine clinical practice. The secondary objectives of the study are to assess short-term persistence to treatment; to assess long-term persistence on treatment; to assess the effect of DRF on relapses; to assess the impact of DRF on cognition; to assess the impact of DRF on participant reported outcomes (PROs) and to explore the real-world safety profile of DRF (ie, gastrointestinal \[GI\] tolerability, lymphocyte dynamics, adverse events \[AEs\] leading to discontinuation, and serious adverse events \[SAEs\]).
Interventions
- DRUG Diroximel Fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2023-04-14 |
Why NCT04746976 stopped before completion
NCT04746976 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 75 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Diroximel Fumarate is the first listed.
NCT04746976 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04746976 about?
NCT04746976 is a clinical study titled "Study of Diroximel Fumarate in the Real-World Setting". The primary objective of the study is to characterize the persistence to therapy in participants with relapsing forms of multiple sclerosis (RMS) treated with diroximel fumarate (DRF) in routine clinical practice. The secondary objectives of the study are to assess short-term persistence to treatmen...
What is the current status of trial NCT04746976?
This trial is currently terminated. The enrollment target is 75 participants. The study started on 2021-03-01. Estimated completion is 2023-04-14.
What interventions are being tested in trial NCT04746976?
The interventions under investigation include: Diroximel Fumarate (DRUG).
Who is sponsoring clinical trial NCT04746976?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI